Mechanism of Qili Qiangxin Capsules in Treating Chronic Heart Failure Based on Theory of Collateral Diseases
10.13422/j.cnki.syfjx.20250415
- VernacularTitle:基于“络病理论”探讨芪苈强心胶囊治疗慢性心力衰竭的作用机制
- Author:
Kun LIAN
1
;
Kexin LIU
1
;
Xueqin WANG
1
;
Fengting LIU
1
;
Liyan LIAO
1
;
Zhixi HU
1
Author Information
1. Hunan University of Chinese Medicine， Changsha 410208， China
- Publication Type:Journal Article
- Keywords:
chronic heart failure;
theory of collateral diseases;
Qili Qiangxin capsules;
clinical effect;
inflammatory response
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(16):146-155
- CountryChina
- Language:Chinese
-
Abstract:
Chronic heart failure （CHF） is the terminal stage of various heart diseases， with high morbidity， mortality， and hospitalization rate. According to the theory of collateral diseases， the core pathogenesis of CHF is blood stasis of collaterals， water retention and stagnation， and pathogen accumulation in collaterals. Accordingly， the treatment should focus on reinforcing healthy Qi to warm Yang， activating blood to dredge collaterals， and excreting water to alleviate edema. On this basis， Qili Qiangxin capsules （QLQX） are created. This prescription can effectively treat chronic heart failure. Modern studies have shown that QLQX contains a variety of pharmacological components such as flavonoids， alkaloids， terpenoids， phenylpropanoids， phenolic acids， and cardiac glycosides. QLQX can improve the cardiac function， inhibit myocardial fibrosis， improve hemodynamics， mitigate inflammation， reduce cardiomyocyte apoptosis， and regulate the nervous system， with mild adverse reactions. This study analyzed the etiology and pathogenesis of CHF based on the theory of collateral diseases， explored the relationship between the prescription and syndrome， and delved into the material basis and mechanism of QLQX in the treatment of CHF， aiming to provide reference for the clinical application and scientific research of QLQX.
